Charles Schwab
PLRX icon

Charles Schwab’s Pliant Therapeutics PLRX Stock Holding History

Charles Schwab’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-251,365
Closed -$292K – 3518
2025
Q2 		$292K Sell
251,365
-137,984
-35% -$195K ﹤0.01% 3318
2025
Q1 		$526K Sell
389,349
-70,035
-15% -$425K ﹤0.01% 3067
2024
Q4 		$6.05M Buy
459,384
+2,721
+0.6% +$37.1K ﹤0.01% 2251
2024
Q3 		$5.12M Buy
456,663
+19,281
+4% +$241K ﹤0.01% 2366
2024
Q2 		$4.7M Buy
437,382
+7,096
+2% +$91.5K ﹤0.01% 2384
2024
Q1 		$6.41M Buy
430,286
+6,090
+1% +$100K ﹤0.01% 2196
2023
Q4 		$7.68M Buy
424,196
+5,990
+1% +$91.1K ﹤0.01% 2127
2023
Q3 		$7.25M Buy
418,206
+61,376
+17% +$1.06M ﹤0.01% 2084
2023
Q2 		$6.47M Buy
356,830
+140,314
+65% +$3.32M ﹤0.01% 2122
2023
Q1 		$5.76M Buy
216,516
+43,860
+25% +$1.25M ﹤0.01% 2137
2022
Q4 		$3.34M Buy
172,656
+3,778
+2% +$79K ﹤0.01% 2399
2022
Q3 		$3.53M Buy
168,878
+72,336
+75% +$1.38M ﹤0.01% 2399
2022
Q2 		$774K Sell
96,542
-70,235
-42% -$450K ﹤0.01% 2890
2022
Q1 		$1.17M Buy
166,777
+4,789
+3% +$48.9K ﹤0.01% 2792
2021
Q4 		$2.19M Buy
161,988
+3,827
+2% +$60.8K ﹤0.01% 2681
2021
Q3 		$2.67M Buy
158,161
+63,282
+67% +$1.34M ﹤0.01% 2631
2021
Q2 		$2.76M Buy
94,879
+1,358
+1% +$42.3K ﹤0.01% 2613
2021
Q1 		$3.68M Buy
93,521
+29,576
+46% +$960K ﹤0.01% 2443
2020
Q4 		$1.45M Buy
63,945
+933
+1% +$23.4K ﹤0.01% 2682
2020
Q3 		$1.43M Buy
+63,012
New +$1.57M ﹤0.01% 2595

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Charles Schwab's PLRX Position: Q3 2025 in Review

Charles Schwab sold out of Pliant Therapeutics (PLRX) in Q3 2025, closing a stake of 251,365 shares — an estimated $292K sold.

Charles Schwab first reported a position in PLRX in Q3 2020 and held it in 20 quarters. The position peaked at $7.68M in Q4 2023. 99 funds tracked by Wall St. Rank hold PLRX as of Q3 2025.

  • Charles Schwab reported no remaining Pliant Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Charles Schwab sold 251,365 Pliant Therapeutics shares in Q3 2025, an estimated $292K.
  • Charles Schwab first reported a position in Pliant Therapeutics in Q3 2020 and held it in 20 quarters.
  • Charles Schwab's Pliant Therapeutics position peaked at $7.68M in Q4 2023.
  • 99 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2025.

Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.